Health Services AccessibilityHACENCT07669168
Health Ahead Comparative Effectiveness Study
A study testing AI-Assisted Screening Interpretation (AI Reads) and Human-Only Screening Interpretation in people with Health Services Accessibility and Rural Health, run by William Brandenburg, MD at 1 site in United States.
Trial summary
The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Health Services Accessibility, Rural Health, Medically Underserved Area
- What is being tested?
- AI-Assisted Screening Interpretation (AI Reads) and Human-Only Screening Interpretation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000,000 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jun 2026to 31 Dec 2099
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative
- Willing to participate in longitudinal follow-up.
Who cannot join
- Age under 18 years.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Longevity Metrics
Boulder, Colorado, 80301
William Brandenburg, MD, 3035010016, info@longevitymetrics.org
About this study
Official title: Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening
The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each change is isolated as a single variable against current practice, and every comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, so results accumulate on a consistent yardstick across the life of the platform.
The first comparison evaluates AI-assisted versus human-only interpretation ("reads") of screening data. Subsequent pre-planned comparisons, added by protocol amendment, evaluate static versus interactive personalized report delivery; mobile community versus fixed laboratory screening; and a hybrid medical-droid-plus-human delivery model versus human-only screening.
Read the detailed description
Access to comprehensive preventive health screening is profoundly unequal. Geographic, economic, and systemic barriers leave medically underserved populations, including rural, frontier, and isolated communities, with little or no access to screening deep enough to identify disease before symptoms occur. The long-term aim is a fully automated preventive screening system deployable anywhere people live. Reaching it safely requires testing each change to the screening model one variable at a time, against current practice.
The study is therefore a standing sequential comparative-effectiveness platform. Each comparison isolates a single change, holds every other element of the screening experience constant, and is evaluated against the same core outcome set. As one comparison concludes, the next opens by protocol amendment.
Two principles govern every comparison. First, allocation is randomized wherever participant-level random assignment is feasible, non-randomized only where it is not, as in comparisons of screening location. Second, every comparison is registered with non-inferiority as the primary hypothesis: each step toward a more automated, more broadly deployable model must show it does not degrade outcomes relative to current practice by more than a pre-specified margin. Superiority is a pre-specified secondary in a hierarchical, gatekeeping sequence. No numeric margins are fixed at registration; each is set per comparison by a rule anchored to a validated minimal clinically important difference where one exists, and locked before that comparison's data are analyzed. Each non-inferiority comparison reports intention-to-treat and per-protocol analyses, and a conclusion requires agreement between them.
The active comparison and the planned comparison sequence are set out below. Comparison 1 (active): AI-assisted versus human-only interpretation ("reads") of screening data. Arms complete identical screening for their visit type and differ only in whether the acquired data receive an AI-generated read. A physician of record reviews and signs every released interpretation in all arms. The comparison runs in two strata by screening complexity, randomized 1:1 within each. The primary contrast combines the strata; each stratum is also analyzed separately. The primary hypothesis is that AI-assisted interpretation is non-inferior to human-only interpretation on health activation.
Planned comparison - static versus interactive personalized health report delivery. Both arms complete identical screening and differ only in the report received. The interactive report lets participants adjust their own behaviors and diagnostic inputs in real time and see the projected effect on composite scores, estimated biological age, and aging trajectory. Randomized.
Planned comparison - mobile community screening versus fixed laboratory screening in medically underserved populations. Because assignment follows the site at which a participant presents, this comparison is not randomized at the participant level.
Planned comparison - a hybrid delivery model combining medical droids, one registered nurse, and remote physician oversight, versus human-only screening.
Future comparison - fully automated screening performed by medical droids with remote physician review, versus the hybrid model.
Future comparison - reduced-capture screening versus the full screening battery, testing how far the acquired input can be reduced while preserving what the screening delivers.
This study is one of four that compound into one system. The 100-Year Human Aging Study (NCT07563777) supplies the clinical data and validates what it means for health, disease, disability, and death. The Human Observatory Study (NCT07646782) does the same with sociodemographic and environmental data, and receives each model's geographic residuals. The Longevity Metrics AI/ML Development Study (NCT pending approval) builds the models that make automation, prediction, and broad utilization possible. This study moves the screening toward increasing automation and mobility while maintaining quality.
- Conditions
- Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services, Patient Participation, Health Behavior
- Being tested
- AI-Assisted Screening Interpretation (AI Reads), Human-Only Screening Interpretation
- Keywords
- Sequential Platform Trial, Interactive Health Report, Health Activation, Mobile Health Screening, Comparative Effectiveness, Health Equity, Rural Health, Medically Underserved, Preventive Medicine, Patient Engagement, Cardiopulmonary Exercise Testing, Body Composition, DEXA, Health Ahead Bus, Mobile Clinic, Automated Screening, Medical Droids, Biological Age, Healthspan, Longevity
- Medical subject headings
- Patient Participation, Health Behavior, Cardiovascular Diseases, Metabolic Syndrome, Cognitive Dysfunction, Frailty, Chronic Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-Assisted Screening Interpretation (AI Reads)Behavioural
An AI-generated read of the acquired screening battery is produced and presented to the physician of record as a clinical aid. All models used are third-party models, executed unmodified on Longevity Metrics clinical infrastructure. The physician reviews each read, records a structured judgment before sign-off, and then produces and signs the released interpretation, which may adopt, modify, or reject any read.
Human-Only Screening InterpretationBehavioural
All acquired screening data, images, tracings, and laboratory results are interpreted by the physician of record and qualified clinical staff under physician supervision, by standard practice and without AI decision support. This is the current standard of care and the active comparator.
| Study group | Role | What they receive |
|---|---|---|
| Human-Only Screening Interpretation | Active comparator | Participants receive comprehensive preventive health screening under the standard of care for the comparison in progress. In the active comparison, all screening data, images, tracings, and laboratory results are interpreted by the physician of record and qualified clinical staff under physician supervision, without AI decision support. Receives: Behavioral: Human-Only Screening Interpretation |
| AI-Assisted Screening Interpretation (AI Reads) | Experimental | Participants receive identical screening with one element modified: the single variable under test in the comparison in progress. In the active comparison, models produce AI-generated reads of the acquired data, presented to the physician of record as a clinical aid. The physician reviews each read, records a structured judgment before sign-off, and produces and signs the released interpretation. The comparison runs in two screening-complexity strata, with a single general model in the simple stratum and a general model plus at least three domain-specific models in the comprehensive stratum. Receives: Behavioral: AI-Assisted Screening Interpretation (AI Reads) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Health Awareness and Action (Non-Inferiority)
Change from baseline in health awareness and action score, measured by the Health Awareness and Action 6-item questionnaire (HAA-6) or its successor instrument, specified and locked in the comparison's Statistical Analysis Plan before first allocation. Change is compared between the experimental arm and the active comparator arm. Non-inferiority is assessed with a one-sided test at the 6-12-month timepoint against a margin pre-specified in the comparison's Statistical Analysis Plan and locked before any analysis of comparison data.
Measured: Baseline (intake, completed at home before the screening visit); 1-2 weeks after screening, at report delivery; 6-12-month follow-up; then periodically from enrollment until death, up to 100 years.
Secondary outcomes (29)
Health Awareness and Action (Superiority)
Conditional on non-inferiority being established in the primary analysis, superiority of the experimental arm over the active comparator arm on change from baseline in health activation score is tested within a pre-specified hierarchical (gatekeeping) sequence, on the same contrasts as the primary analysis, and reported whenever the data support a superiority claim.
Measured: Baseline (intake, completed at home before the screening visit); 1-2 weeks after screening, at report delivery; 6-12-month follow-up; then periodically from enrollment until death, up to 100 years.
Report Efficacy and Utilization
Participant-reported efficacy and utilization of the personalized report, compared between arms, using two items each rated 1-10: (a) "This report helped me understand my health better"; (b) "This report helped me understand what to do to improve my health". Items (a) and (b) are compared across arms.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Unintended Consequences and Psychological Impact
Participant-reported emotional response to receiving personalized risk estimates (estimated biological age, predicted age at death, and predicted causes of death), compared between arms, rated on three bipolar 1-10 scales: anxious or overwhelmed (1) to empowered (10); distressed (1) to motivated (10); and confused (1) to informed (10).
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Completion of Provider-Recommended Health Behavior Changes
On the personalized screening report, the provider specifies the three highest-priority recommended changes, spanning lifestyle, environmental, and medical domains. At each follow-up, participants report for each of the three whether they completed or adhered to it. The primary metric is the number of provider-recommended changes completed (0-3), compared between arms.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Primary Barrier to Non-Completion of Recommended Changes
For each provider-recommended change a participant reports not completing, the participant identifies the single main barrier using a fixed-choice item adapted to that recommendation ("What is the main thing getting in the way of [recommendation]?"). Response options: Time; Money or cost; Access to care or services; Stress or mental health; Sleep; Addiction or substance use; Physical limitations, pain, or symptoms; Knowledge (not sure what to do); Motivation; Habits or routines; Family or relationship demands; Other (free text). The metric is the distribution of selected barriers across non-completed recommendations, compared between arms.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Participant Satisfaction - Longevity Metrics Post-Screening Satisfaction Questionnaire (6-item), Composite Score
Participant satisfaction measured with the Longevity Metrics Post-Screening Satisfaction Questionnaire, a 6-item self-report instrument administered after the participant receives their screening report. Each item is rated on a 1-10 linear scale; items cover perceived value of the report, satisfaction with the tester, the screening, and the data/report/recommendations, and likelihood to recommend Longevity Metrics. A composite score is calculated as the sum of all items (minimum 6, maximum 60); higher scores indicate greater satisfaction. Compared between groups.
Measured: 1 to 2 weeks after health screening (at report delivery)
Complexity-Adjusted Cost-Effectiveness
Complexity-adjusted cost, computed as total direct costs ÷ (screening complexity weight × participants completing screening), where the complexity weight reflects the scope and intensity of the screening battery delivered (e.g., single-modality DEXA versus the full multi-system report-card battery), so that a simpler, lower-cost screen is not credited as artificially more efficient than a broader battery that delivers more. An incremental cost-effectiveness ratio compares complexity-adjusted cost against improvement in the primary endpoint.
Measured: 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Participant Follow-up and Retention
Retention and follow-up completion across the lifelong cohort, compared between arms, assessed by: study retention (proportion of enrolled participants remaining active versus withdrawn or lost to follow-up); follow-up questionnaire completion (proportion completing each scheduled follow-up survey); and in-person re-screening return (proportion returning to the laboratory or mobile site for scheduled repeat testing). Initial follow-up occurs at 6-12 months; follow-up continues for life thereafter, enabling longitudinal ascertainment of chronic disease, adverse health outcomes, and mortality. Differential retention between arms is monitored as a potential source of bias in non-inferiority comparisons.
Measured: 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Longitudinal Health Outcomes and Mortality
All-cause mortality, cause-specific mortality, incident serious health events, and incident chronic disease development, compared between arms as follow-up accumulates through the 100-Year Human Aging Study protocol.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Operational Throughput and Screening Completion
Operational equivalence across arms, assessed by: capacity utilization (time slots filled ÷ total available time slots); no-show rate (proportion of scheduled appointments not attended); and screening completion status (proportion of screenings fully completed, partially completed, or unable to be performed, with reason for non-completion recorded as patient declined, equipment failure, operator failure, or other [free text]). Compared between arms.
Measured: 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Data Quality and Test Validity
Objective data quality and test validity across arms, reported as the proportion of assessments meeting pre-specified quality thresholds, across three categories: (a) CPET test validity - proportion of cardiopulmonary exercise tests with peak respiratory exchange ratio (RER) at or above a pre-specified threshold (>~1.10); (b) instrument calibration - proportion of screening sessions in which the CPET metabolic cart, spirometer (PFT), and DEXA passed calibration/QC within manufacturer-specified thresholds; and (c) effort adequacy - proportion of effort-dependent tests for which provider-rated effort met or exceeded a pre-specified adequacy cutoff (e.g., ≥7 of 10). Compared between arms.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Population Characterization by Arm
Baseline characterization by arm across sociodemographic, geographic, environmental, health history and healthcare utilization domains. Functions as a randomization-balance check where assignment is randomized, and as a substantive between-population comparison in any comparison in which arms draw from different settings.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Screening-Related Adverse Events
Participant-reported adverse events attributed to the screening, captured after each screening visit by a single mark-all-that-apply item: "Did you experience any of the following as a result of your health screening?" Options: musculoskeletal injury; other injury; a fall; dizziness, lightheadedness, or fainting; chest pain or palpitations; shortness of breath; excessive muscle soreness or fatigue; bruising, bleeding, or pain at the blood draw site; pain or discomfort during a test; distress; anxiety; confusion; feeling overwhelmed; trouble sleeping; none; other adverse health event (free text). The metric is the proportion of participants reporting each event category, compared between arms; events are also captured in the trial's standard adverse-event reporting.
Measured: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Change in peak oxygen uptake (VO2peak) measured by cardiopulmonary exercise testing
VO2peak is the highest rate of oxygen consumption achieved during a symptom-limited cardiopulmonary exercise test (CPET), expressed in mL/kg/min. Higher values indicate greater cardiorespiratory fitness. Change is calculated as the difference between successive screenings (follow-up minus baseline) and compared between arms.
Unit of Measure: mL/kg/min
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in heart rate recovery at 2 minutes post-exercise
Heart rate recovery (HRR) at 2 minutes is the difference between peak heart rate at the end of cardiopulmonary exercise testing and the heart rate measured 2 minutes into recovery, expressed in beats per minute (bpm). A larger drop indicates better autonomic function. Change is the difference between successive screenings, compared between arms.
Unit of Measure: bpm
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in maximal handgrip strength by hand dynamometer
Maximal handgrip strength measured with a hand dynamometer, recorded as the single highest value obtained across 2-3 trials in either hand, expressed in kilograms (kg). Higher values indicate greater strength. Change is the difference between successive screenings, compared between arms.
Unit of Measure: kg
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in Sit-to-Rise score
The Sit-to-Rise Test assesses lower-body strength, mobility, flexibility, and balance by requiring the participant to sit on and rise from the floor with minimal support. Scored 0-5 for sitting and 0-5 for rising, summed to a 0-10 composite; higher scores indicate better musculoskeletal function. Change is the difference between successive screenings, compared between arms.
Unit of Measure: Units on a scale (0-10)
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in appendicular lean mass index (ALMI) by DEXA
Appendicular lean mass index is the sum of lean soft-tissue mass in the arms and legs measured by dual-energy X-ray absorptiometry (DXA), divided by height squared, expressed in kg/m². Higher values indicate greater skeletal muscle mass. Change is the difference between successive screenings, compared between arms.
Unit of Measure: kg/m²
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in visceral adipose tissue (VAT) mass by DEXA
Visceral adipose tissue mass estimated by dual-energy X-ray absorptiometry (DXA), expressed in grams (g). Lower values indicate less visceral fat. Change is the difference between successive screenings, compared between arms.
Unit of Measure: grams
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in fasting serum triglycerides
Fasting serum triglyceride concentration measured by a CLIA-certified reference laboratory, expressed in mg/dL. Lower values indicate a more favorable lipid profile. Change is the difference between successive screenings, compared between arms.
Unit of Measure: mg/dL
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in 2-hour post-load glucose during oral glucose tolerance test, measured by continuous glucose monitor
Glucose measured 120 minutes after a 75 g oral glucose load (OGTT) using a continuous glucose monitor (CGM), expressed in mg/dL. Lower values indicate better post-load glucose disposal. Change is calculated as the difference between successive screenings, compared between arms.
Unit of Measure: mg/dL
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in resting mean arterial pressure (MAP)
Resting mean arterial pressure derived from resting brachial systolic (SBP) and diastolic (DBP) blood pressure using MAP = (2 × DBP + SBP) / 3, expressed in mmHg; a single value is reported per assessment. Change is the difference between successive screenings, compared between arms.
Unit of Measure: mmHg
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in number of patient-reported symptoms (Longevity Metrics symptom checklist)
Symptom burden via the Longevity Metrics 24-item self-report checklist; participants mark all that apply: (1) chest pain or pressure; (2) shortness of breath on minimal/moderate exertion; (3) dizziness or fainting; (4) fever or night sweats; (5) fatigue; (6) erectile dysfunction; (7) persistent cough; (8) coughing up blood; (9) difficulty swallowing; (10) unexplained weight loss; (11) excessive thirst/urination; (12) abdominal pain; (13) nausea or vomiting; (14) diarrhea; (15) constipation; (16) blood in stool or urine; (17) headaches; (18) weakness or numbness; (19) vision changes; (20) memory problems; (21) new lump or swelling; (22) non-healing wound or sore; (23) skin rash; (24) a fall from loss of balance, dizziness, or weakness in the last 6 months (not during sports/recreation). Each item and "Other" score 1; "None of the above" scores 0. Change is the difference between successive screenings, compared between arms.
Unit of measure: number of symptoms marked
Measured: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Interpretation Agreement (Physician Rating of AI Read)
Description: Distribution of the physician's 1-10 rating of agreement with each AI-generated read, recorded before sign-off. Reported overall and by model, including the proportion in the 8-10 agreement band. Scale runs from 1, complete disagreement, to 10, complete agreement. Arm B only
Measured: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Interpretation Divergence
Proportion of AI-generated reads rated at or below a pre-specified agreement threshold, reported by model together with the accompanying distribution of safety ratings. Arm B only.
Measured: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Safety Profile of AI Reads
Distribution of the physician's 1-10 rating of the potential for patient harm had the AI read been acted upon as written, recorded before sign-off. Reported overall and by model, including the proportion in the 1-3 band and the disposition of every read so rated. Scale runs from 1, high potential for serious harm, to 10, no potential for patient harm. Arm B only.
Measured: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Override Rate
The proportion of reads the physician changed. At sign-off the physician records whether the released interpretation differs substantively from each read; override rate is the share where it does, reported overall and by model, and reported against the safety ratings for the same reads. The agreement rating captures what the physician thought of a read; this measure captures what the physician did with it. Arm B only.
Measured: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Complexity of the Released Interpretation
Finding counts, referral recommendations, and total word count appearing in the released interpretation (impression and 3 recommendations), compared between arms.
Measured: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Physician Review Burden
Time to physician sign-off per read and per participant, compared between arms.
Measured: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2026
- Study start9 Jun 2026
- Primary completion31 Dec 2099 (estimated)
- Study completion31 Dec 2099 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Health Services AccessibilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a pragmatic, sequential comparative-effectiveness platform study of how preventive health screening is delivered. Each comparison isolates a single change to the screening model against current practice, holds every other element constant, and is evaluated on a common core outcome set, with non-inferiority as the primary hypothesis. Comparisons activate sequentially by protocol amendment; each is a parallel-arm comparison, and the arms registered on this record reflect the active comparison. Comparison 1 (active) - AI-assisted versus human-only interpretation ("reads") of screening data. Both arms complete identical screening and differ only in whether the acquired data receive an AI-generated read; a physician of record reviews and signs every released interpretation in both arms. Allocation is randomized 1:1 within two strata defined by screening complexity.
- Masking
- None (open label)
- Enrolment
- 1,000,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- William Brandenburg, MD
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor-investigator, William Brandenburg, MD, Longevity Metrics, Inc.
- Investigators
- William Brandenburg, MD, Principal investigator, Longevity Metrics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07669168
- Sponsor's protocol ID
- HealthAheadCE
- Other IDs
- IORG0012336; IRB00014601
- Acronym
- HACE
- Status last verified
- Sep 2026
- First submitted
- 9 Jun 2026
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data are not shared. The complete participant record includes facial and voice recordings, genomic data, and neighborhood-resolution geography, and cannot be de-identified; it is never released. Identifiable data are accessed only by approved researchers working within Longevity Metrics secure facilities under data use agreements, with no data removed. Specific derived, aggregate, and statistical outputs are de-identified to HIPAA Safe Harbor standards and may be published, shared with collaborators, or contributed to open-access research databases. Models, risk estimates, and analytic findings derived from the research data may be provided to external organizations or used commercially; no participant record and no dataset containing participant data is transferred.
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening
- ClinicalTrials.gov ID
- NCT07669168
- Acronym / sponsor ID
- HACE / HealthAheadCE
- Conditions
- Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services, Patient Participation, Health Behavior
- Keywords
- Sequential Platform Trial, Interactive Health Report, Health Activation, Mobile Health Screening, Comparative Effectiveness, Health Equity, Rural Health, Medically Underserved
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,000,000 participants (estimated)
- Lead sponsor
- William Brandenburg, MDIndustry (pharma, biotech, devices)
- Study start
- 9 Jun 2026 (actual)
- Primary completion
- 31 Dec 2099 (estimated)
- Study completion
- 31 Dec 2099 (estimated)
- First posted
- 25 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each change is isolated as a single variable against current practice, and every comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, so results accumulate on a consistent yardstick across the life of the platform.
The first comparison evaluates AI-assisted versus human-only interpretation ("reads") of screening data. Subsequent pre-planned comparisons, added by protocol amendment, evaluate static versus interactive personalized report delivery; mobile community versus fixed laboratory screening; and a hybrid medical-droid-plus-human delivery model versus human-only screening.
Detailed description
Access to comprehensive preventive health screening is profoundly unequal. Geographic, economic, and systemic barriers leave medically underserved populations, including rural, frontier, and isolated communities, with little or no access to screening deep enough to identify disease before symptoms occur. The long-term aim is a fully automated preventive screening system deployable anywhere people live. Reaching it safely requires testing each change to the screening model one variable at a time, against current practice.
The study is therefore a standing sequential comparative-effectiveness platform. Each comparison isolates a single change, holds every other element of the screening experience constant, and is evaluated against the same core outcome set. As one comparison concludes, the next opens by protocol amendment.
Two principles govern every comparison. First, allocation is randomized wherever participant-level random assignment is feasible, non-randomized only where it is not, as in comparisons of screening location. Second, every comparison is registered with non-inferiority as the primary hypothesis: each step toward a more automated, more broadly deployable model must show it does not degrade outcomes relative to current practice by more than a pre-specified margin. Superiority is a pre-specified secondary in a hierarchical, gatekeeping sequence. No numeric margins are fixed at registration; each is set per comparison by a rule anchored to a validated minimal clinically important difference where one exists, and locked before that comparison's data are analyzed. Each non-inferiority comparison reports intention-to-treat and per-protocol analyses, and a conclusion requires agreement between them.
The active comparison and the planned comparison sequence are set out below. Comparison 1 (active): AI-assisted versus human-only interpretation ("reads") of screening data. Arms complete identical screening for their visit type and differ only in whether the acquired data receive an AI-generated read. A physician of record reviews and signs every released interpretation in all arms. The comparison runs in two strata by screening complexity, randomized 1:1 within each. The primary contrast combines the strata; each stratum is also analyzed separately. The primary hypothesis is that AI-assisted interpretation is non-inferior to human-only interpretation on health activation.
Planned comparison - static versus interactive personalized health report delivery. Both arms complete identical screening and differ only in the report received. The interactive report lets participants adjust their own behaviors and diagnostic inputs in real time and see the projected effect on composite scores, estimated biological age, and aging trajectory. Randomized.
Planned comparison - mobile community screening versus fixed laboratory screening in medically underserved populations. Because assignment follows the site at which a participant presents, this comparison is not randomized at the participant level.
Planned comparison - a hybrid delivery model combining medical droids, one registered nurse, and remote physician oversight, versus human-only screening.
Future comparison - fully automated screening performed by medical droids with remote physician review, versus the hybrid model.
Future comparison - reduced-capture screening versus the full screening battery, testing how far the acquired input can be reduced while preserving what the screening delivers.
This study is one of four that compound into one system. The 100-Year Human Aging Study (NCT07563777) supplies the clinical data and validates what it means for health, disease, disability, and death. The Human Observatory Study (NCT07646782) does the same with sociodemographic and environmental data, and receives each model's geographic residuals. The Longevity Metrics AI/ML Development Study (NCT pending approval) builds the models that make automation, prediction, and broad utilization possible. This study moves the screening toward increasing automation and mobility while maintaining quality.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a pragmatic, sequential comparative-effectiveness platform study of how preventive health screening is delivered. Each comparison isolates a single change to the screening model against current practice, holds every other element constant, and is evaluated on a common core outcome set, with non-inferiority as the primary hypothesis. Comparisons activate sequentially by protocol amendment; each is a parallel-arm comparison, and the arms registered on this record reflect the active comparison. Comparison 1 (active) - AI-assisted versus human-only interpretation ("reads") of screening data. Both arms complete identical screening and differ only in whether the acquired data receive an AI-generated read; a physician of record reviews and signs every released interpretation in both arms. Allocation is randomized 1:1 within two strata defined by screening complexity.
| Arm | Type | Receives |
|---|---|---|
| Human-Only Screening Interpretation | Active comparator | Behavioral: Human-Only Screening InterpretationParticipants receive comprehensive preventive health screening under the standard of care for the comparison in progress. In the active comparison, all screening data, images, tracings, and laboratory results are interpreted by the physician of record and qualified clinical staff under physician supervision, without AI decision support. |
| AI-Assisted Screening Interpretation (AI Reads) | Experimental | Behavioral: AI-Assisted Screening Interpretation (AI Reads)Participants receive identical screening with one element modified: the single variable under test in the comparison in progress. In the active comparison, models produce AI-generated reads of the acquired data, presented to the physician of record as a clinical aid. The physician reviews each read, records a structured judgment before sign-off, and produces and signs the released interpretation. The comparison runs in two screening-complexity strata, with a single general model in the simple stratum and a general model plus at least three domain-specific models in the comprehensive stratum. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18 years or older
- Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative
- Willing to participate in longitudinal follow-up.
Key exclusion criteria (1 listed)
- Age under 18 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-Assisted Screening Interpretation (AI Reads)An AI-generated read of the acquired screening battery is produced and presented to the physician of record as a clinical aid. All models used are third-party models, executed unmodified on Longevity Metrics clinical infrastructure. The physician reviews each read, records a structured judgment before sign-off, and then produces and signs the released interpretation, which may adopt, modify, or reject any read. | Behavioural | AI-Assisted Screening Interpretation (AI Reads) |
| Human-Only Screening InterpretationAll acquired screening data, images, tracings, and laboratory results are interpreted by the physician of record and qualified clinical staff under physician supervision, by standard practice and without AI decision support. This is the current standard of care and the active comparator. | Behavioural | Human-Only Screening Interpretation |
Primary outcome
Health Awareness and Action (Non-Inferiority)
Time frame: Baseline (intake, completed at home before the screening visit); 1-2 weeks after screening, at report delivery; 6-12-month follow-up; then periodically from enrollment until death, up to 100 years.
Change from baseline in health awareness and action score, measured by the Health Awareness and Action 6-item questionnaire (HAA-6) or its successor instrument, specified and locked in the comparison's Statistical Analysis Plan before first allocation. Change is compared between the experimental arm and the active comparator arm. Non-inferiority is assessed with a one-sided test at the 6-12-month timepoint against a margin pre-specified in the comparison's Statistical Analysis Plan and locked before any analysis of comparison data.
29 secondary outcomes
Health Awareness and Action (Superiority)
Time frame: Baseline (intake, completed at home before the screening visit); 1-2 weeks after screening, at report delivery; 6-12-month follow-up; then periodically from enrollment until death, up to 100 years.
Report Efficacy and Utilization
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Unintended Consequences and Psychological Impact
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Completion of Provider-Recommended Health Behavior Changes
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Primary Barrier to Non-Completion of Recommended Changes
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Participant Satisfaction - Longevity Metrics Post-Screening Satisfaction Questionnaire (6-item), Composite Score
Time frame: 1 to 2 weeks after health screening (at report delivery)
Complexity-Adjusted Cost-Effectiveness
Time frame: 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Participant Follow-up and Retention
Time frame: 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Longitudinal Health Outcomes and Mortality
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Operational Throughput and Screening Completion
Time frame: 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Data Quality and Test Validity
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Population Characterization by Arm
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Screening-Related Adverse Events
Time frame: Baseline, 6-12-month follow-up, then periodically from enrollment until death, up to 100 years.
Change in peak oxygen uptake (VO2peak) measured by cardiopulmonary exercise testing
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in heart rate recovery at 2 minutes post-exercise
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in maximal handgrip strength by hand dynamometer
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in Sit-to-Rise score
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in appendicular lean mass index (ALMI) by DEXA
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in visceral adipose tissue (VAT) mass by DEXA
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in fasting serum triglycerides
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in 2-hour post-load glucose during oral glucose tolerance test, measured by continuous glucose monitor
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in resting mean arterial pressure (MAP)
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Change in number of patient-reported symptoms (Longevity Metrics symptom checklist)
Time frame: Baseline, 6-12 months, then periodically through study completion (up to 100 years)
Interpretation Agreement (Physician Rating of AI Read)
Time frame: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Interpretation Divergence
Time frame: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Safety Profile of AI Reads
Time frame: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Override Rate
Time frame: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Complexity of the Released Interpretation
Time frame: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Physician Review Burden
Time frame: At report generation for each participant, across the index screening and any repeat screening within the Comparison 1 intervention period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Longevity Metrics ResearchLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data are not shared. The complete participant record includes facial and voice recordings, genomic data, and neighborhood-resolution geography, and cannot be de-identified; it is never released. Identifiable data are accessed only by approved researchers working within Longevity Metrics secure facilities under data use agreements, with no data removed. Specific derived, aggregate, and statistical outputs are de-identified to HIPAA Safe Harbor standards and may be published, shared with collaborators, or contributed to open-access research databases. Models, risk estimates, and analytic findings derived from the research data may be provided to external organizations or used commercially; no participant record and no dataset containing participant data is transferred.
Related trials for Health Services Accessibility
Not yet recruiting
Pilot Study to Co-create and Implement a Multicomponent Intervention to Reduce Mental Health Stigma in Primary Care
Mental Health, Stigma of Mental Illness
Active, not recruiting
UCSD RELINK: Connecting Adults To Supportive Services
Health Care Utilization
Active, not recruitingPhase 3
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Haemophilia A (Moderate or Severe)
Recruiting
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Leukemia, Lymphoma
RecruitingPhase 2
Impact of Smell Testing on Health Outcomes
Olfactory Dysfunction, Wellbeing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
William Brandenburg, MD principal investigator
Longevity Metrics
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-Assisted Screening Interpretation (AI Reads) and Human-Only Screening Interpretation in people with Health Services Accessibility and Rural Health, run by William Brandenburg, MD at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact William Brandenburg, MD (13035010016, info@longevitymetrics.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Health Awareness and Action (Non-Inferiority) (time frame: Baseline (intake, completed at home before the screening visit); 1-2 weeks after screening, at report delivery; 6-12-month follow-up; then periodically from enrollment until death, up to 100 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.